Abstract Library

#4142 Metastatic insulinoma – A clinical conundrum

Introduction: We present a case series of metastatic insulinoma from a single tertiary referral centre, highlighting heterogeneity in presentations, management, and multimodal therapy.

Conference:

Presenting Author:

Authors: Mathara Diddhenipothage S, Matheou M, Wilson S, Naseer A, Moore N,

Keywords: Metastatic insulinoma, hepatic metastases, peri-lesional steatosis,

#686 Hepatic Arterial Embolization for Gastroenteropancreatic NET Liver Metastases

Introduction: Selective hepatic arterial embolization (HAE) with polyvinyl alcohol particles has been shown to be equivalent to chemoembolization for patients with hepatic gastroenteropancreatic (GEP) neuroendocrine metastases. There remains debate about its clinical effectiveness and which patients benefit from treatment.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Wilson C

Authors: Wilson C, Vallance A, Bernstone G, Williams R, Jackson R,

Keywords: hepatic arterial embolisation,

#321 Role of VEGFR-2, P53, P53R2 and Ki-67 Expression in Metastatic Carcinoid Cancer

Introduction: Ki-67 expression is a well-known prognostic factor in neuroendocrine tumors. The role of modified expression of p53, p53R2 and VEGFR2 in this disease’s liver metastases has not been established.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Spencer R, Costa W, Salvador H, Diniz A, Cruz C,

Keywords: neuroendocrine tumor, liver metastasis, P53, P53R2, VEGFR2, Ki-67 ,

#255 The Carcinoid Syndrome Caused by Retroperitoneal Carcinoid Tumors

Introduction: The carcinoid syndrome is caused by increased levels of serotonin and is mostly seen in cases of carcinoid tumor in the small bowel and liver metastases, as there is a very high first pass effect.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Wilson B, Nielsen H,

Keywords: carcinoid syndrome, NET, retroperitoneal mass,

#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional

Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Johanson V, Wilson B, Abrahamsson A, Jianu C, Calissendorff J,

Keywords: neuroendocrine tumors, NET, self-administration, somatostatin analogs, lanreotide,